My Policy Hub

Improving health is our policy

  • Dashboard
  • Impact Insights
  • Issues
  • ACA Now
  • Search
  • Contact
  • Dashboard
  • Impact Insights
  • Issues
  • ACA Now
  • Search
  • Contact

WHG - EpiPen and the Pricing Debate – Congressional Oversight and Campaign Proposals

August 30, 2016

Summary

The chorus of disapproval about the cost of EpiPen prescriptions reached a crescendo last week after the maker of the drug, Mylan, was widely lambasted for drastic price increases in the product which is widely used to combat potentially life-threatening allergic reactions. Over the past decade, the list price for a package of two injectors has jumped from $94 to $608; Mylan raised the price by 15 percent three separate times since 2014. The EpiPen has garnered more attention recently thanks, in part, to timing: with the beginning of the school year, many parents suddenly found that the device cost more than ever before.

Read Source Article
Read Full Analysis
Source
  • Wynne Health Group
Author(s)
  • Wynne Health Group
Healthcare Topics
  • Cost-Sharing
  • Costs
  • Food and Drug Administration
  • Generic Drugs
  • Pharmacies
  • Pharmacy Benefit Managers

ABOUT

  • Home
  • About Policy Hub
  • Free Newsletter
  • Team
  • Mission and Values
  • Contact Us

Contact Us

Impact Health Policy Partners 1301 K Street, NW, Suite 300W
Washington, D.C. 20005

(202) 309-0796
Contact Us

Copyright © 2025 ‐ Impact Health Policy Partners ‐ All Rights Reserved ‐ Privacy Policy ‐ Terms and Conditions ‐ Log in